niacinamide has been researched along with tacrolimus in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (33.33) | 29.6817 |
2010's | 6 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Hashii, M; Higashida, H; Minabe, Y | 1 |
Rosenkrantz, WS | 1 |
Igarashi, H; Katayama, Y | 1 |
Düber, C; Galle, PR; Heise, M; Hoppe-Lotichius, M; Koch, S; Niederle, IM; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA | 1 |
Dawidowski, M; Gajzlerska, W; Gutkowska, B; Klimaszewska, M; Król, M; Turło, J | 1 |
Lehner, GM; Linek, M | 1 |
Banovic, F; Howerth, E; Jerry, C | 1 |
Cao, S; Ruan, W; Wan, T; Wang, Y; Wu, C; Xu, Y; Yu, K; Zhai, Y | 1 |
2 review(s) available for niacinamide and tacrolimus
Article | Year |
---|---|
Pemphigus: current therapy.
Topics: Animals; Antirheumatic Agents; Azathioprine; Chlorambucil; Cyclophosphamide; Cyclosporine; Dapsone; Dog Diseases; Dogs; Glucocorticoids; Immunoglobulins, Intravenous; Mycophenolic Acid; Niacinamide; Organogold Compounds; Pemphigus; Sulfasalazine; Tacrolimus; Tetracycline | 2004 |
[Advances in the diagnosis and treatment of cerebral ischemia during the acute phase].
Topics: Acute-Phase Reaction; Antipyrine; Brain Ischemia; Cerebrovascular Circulation; Drug Design; Drug Therapy, Combination; Edaravone; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Nerve Growth Factors; Neuroprotective Agents; Niacinamide; Recombinant Proteins; Tacrolimus; Time Factors; Tissue Plasminogen Activator | 2003 |
7 other study(ies) available for niacinamide and tacrolimus
Article | Year |
---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
cADP-ribose potentiates cytosolic Ca2+ elevation and Ca2+ entry via L-type voltage-activated Ca2+ channels in NG108-15 neuronal cells.
Topics: Adenosine Diphosphate Ribose; Biological Transport; Calcium; Calcium Channels, L-Type; Cells, Cultured; Cyclic ADP-Ribose; Cytosol; Ion Channel Gating; Manganese; Membrane Potentials; Models, Biological; NAD; Neurons; Niacinamide; Nifedipine; Patch-Clamp Techniques; Ryanodine; Ryanodine Receptor Calcium Release Channel; Tacrolimus | 2000 |
Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sirolimus; Sorafenib; Tacrolimus | 2012 |
Enhancement of tacrolimus productivity in Streptomyces tsukubaensis by the use of novel precursors for biosynthesis.
Topics: Biotechnology; Culture Media; Fermentation; Kinetics; NAD; NADP; Niacin; Niacinamide; Picolinic Acids; Streptomyces; Tacrolimus | 2012 |
A case of vesicular cutaneous lupus erythematosus in a Border collie successfully treated with topical tacrolimus and nicotinamide-tetracycline.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Dog Diseases; Dogs; Drug Combinations; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Male; Niacinamide; Tacrolimus; Tetracycline; Vitamin B Complex | 2013 |
Tacrolimus therapy for dermal arteritis of the nasal philtrum refractory to surgery and anti-inflammatory therapy (doxycycline/niacinamide and topical fluocinolone) in a dog.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Arteritis; Dog Diseases; Dogs; Doxycycline; Fluocinolone Acetonide; Lip; Male; Niacinamide; Nose; Tacrolimus | 2018 |
Tacrolimus nanoparticles based on chitosan combined with nicotinamide: enhancing percutaneous delivery and treatment efficacy for atopic dermatitis and reducing dose.
Topics: Administration, Cutaneous; Animals; Chitosan; Dermatitis, Atopic; Dinitrochlorobenzene; Drug Delivery Systems; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Niacinamide; Ointments; Rats, Sprague-Dawley; Skin; Skin Absorption; Tacrolimus; Treatment Outcome | 2018 |